Back to browse

EXP002453

Paper

Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin (2024)

Peptide

RGD-decorated liposome / dipalmitoyl-GRGDSPA

Sequence: GRGDSPA

RNA

miRNA

All experiment fields

Experiment Id EXP002453
Paper Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin
Peptide RGD-decorated liposome / dipalmitoyl-GRGDSPA
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed no
Label Confidence high
In Vitro Functional Effect yes
Endosomal Escape Evidence
Peptide Concentration not separately specified; dipalmitoyl-GRGDSPA included in lipid mixture at DSPC:cholesterol:dipalmitoyl-GRGDSPA 7:3:1 mM
Rna Concentration In vitro assays used 10 nM miR-34a for apoptosis/gene-expression experiments; MTT included 5-10 nM miR-34a with cisplatin held at 16 ug/mL in combination assays
Mixing Ratio Lipid composition DSPC:cholesterol:dipalmitoyl-GRGDSPA = 7:3:1 mM; protamine/miR-34a complex formed before liposome hydration
Formulation Format RGD-modified liposome co-delivering cisplatin and protamine-complexed miR-34a
Formulation Components DSPC, cholesterol, dipalmitoyl-GRGDSPA, protamine, miR-34a, cisplatin
Size Nm 213.90
Zeta Mv -10.70
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells MCF-7 human breast cancer cells
Animal Model
Administration Route cell culture exposure to liposomal formulations
Output Type cell viability; apoptosis; apoptosis-related gene expression
Output Value miR34a-Cis-Lip-RGD IC50 3.90 +/- 0.23 nM at 24 h; apoptosis 76.24%; increased Bax expression and decreased Bcl-2 expression relative to controls
Output Units
Output Notes Functional in vitro RNA-associated antitumor effect shown, but in vitro activity does not qualify as delivery_success_class = 1.
Toxicity Notes Hemolysis assay: cisplatin caused RBC lysis, while liposomal encapsulation significantly decreased lysis compared with free cisplatin.
Curation Notes